Safety of intravenous immunoglobulin treatment.
AUTOR(ES)
Atrah, H I
RESUMO
In a prospective clinical and biochemical study of 16 patients treated with high doses of an immunoglobulin product that had been modified for intravenous use by mild pepsin treatment at pH 4 no evidence of hepatitis could be found. This contrasts with recent reports that intravenous immunoglobulin products can apparently transmit non-A, non-B hepatitis.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=499468Documentos Relacionados
- High-dose intravenous human immunoglobulin in polymyositis resistant to treatment.
- Requirements for safety and quality of intravenous immunoglobulin G preparations.
- Treatment of acute pandysautonomia with intravenous immunoglobulin.
- Intravenous immunoglobulin treatment in neurological diseases.
- Successful treatment of stiff man syndrome with intravenous immunoglobulin.
